Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin

Journal of Gastroenterology

Volumn 48, Issue 12, 2013, Pages 1401-1410

  Yi, Nam Joon ^a   Choi, Jong Young ^b   Suh, Kyung Suk ^a   Cho, Jai Young ^a   Baik, Minjung ^c   Hong, Geun ^a   Lee, Kwang Woong ^a   Kim, Won ^d   Kim, Yoon Jun ^a   Yoon, Jung Hwan ^a   Lee, Hyo Suk ^a   Kim, Dong Goo ^b  

^a Seoul National University College of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d Seoul National University Boramae Hospital   (South Korea)

Author keywords

Entecavir; Hepatitis B; Hepatitis B immunoglobulin; Hepatitis B prophylaxis; Liver transplantation

Indexed keywords

ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ABSENCE OF SIDE EFFECTS; ACUTE GRAFT REJECTION; ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHEMOEMBOLIZATION; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DNA DETERMINATION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTENTION TO TREAT ANALYSIS; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MODEL FOR END STAGE LIVER DISEASE SCORE; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; RECURRENT INFECTION; REOPERATION; SURVIVAL RATE; TREATMENT DURATION;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GUANINE; HEPATITIS B; HUMANS; IMMUNOGLOBULINS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84891493338     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0761-x     Document Type: Article

References (26)

1. Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, et al. National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology. 2009;49:S4-12.
2. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet. 2003;362:2089-94.
3. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993;329:1842-7.
4. Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology. 1996;24:1327-33.
5. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339:61-8.
6. Lo CM, Cheung ST, Lai CL, Liu CL, Ng IO, Yuen MF, et al. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg. 2001;233:276-81.
7. Markowitz JS, Seu P, Goss JA, Yersiz H, Markmann JF, Farmer DG, et al. Liver transplantation for decompensated cirrhosis after jejunoileal bypass: a strategy for management. Transplantation. 1998;65:570-2.
8. Dumortier J, Chevallier P, Scoazec JY, Berger F, Boillot O. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. Am J Transplant. 2003;3:999-1002.
9. Yi NJ, Suh KS, Cho JY, Kwon CH, Lee KW, Joh JW, et al. Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 2007;13:451-8.
10. Hwang S, Ahn CS, Song GW, Kim KH, Moon DB, Oh HB, et al. Posttransplantation prophylaxis with primary high-dose hepatitis B immunoglobulin monotherapy and complementary preemptive antiviral add-on. Liver Transpl. 2011;17:456-65.
11. Rao W, Wu X, Xiu D. Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis. Transpl Int. 2009;22:387-94.
12. Katz LH, Paul M, Guy DG, Tur-Kaspa R. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis. Transpl Infect Dis. 2010;12:292-308.
13. Loomba R, Rowley AK, Wesley R, Smith KG, Liang TJ, Pucino F, et al. Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol. 2008;6:696-700.
14. Gane EJ, Angus PW, Strasser S, Crawford DH, Ring J, Jeffrey GP, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology. 2007;132:931-7.
15. Angus PW, Patterson SJ. Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin/antiviral regimen? Liver Transpl. 2008;14(Suppl 2):S15-22.
16. Chun J, Kim W, Kim BG, Lee KL, Suh KS, Yi NJ, et al. High viremia, prolonged Lamivudine therapy and recurrent hepatocellular carcinoma predict posttransplant hepatitis B recurrence. Am J Transplant. 2010;10:1649-59.
17. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661-2.
18. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 2009;49:1503-14.
19. Fung J, Cheung C, Chan SC, Yuen MF, Chok KS, Sharr W, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology. 2011;141:1212-9.
20. Song BC, Cui XJ, Kim H. Hepatitis B virus genotypes in Korea: an endemic area of hepatitis B virus infection. Intervirology. 2005;48:133-7.
21. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology. 2008;48:1460-6.
22. Cholongitas E, Vasiliadis T, Antoniadis N, Goulis I, Papanikolaou V, Akriviadis E. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation. Transpl Infect Dis.
23. Jiang L, Yan L, Li B, Wen T, Zhao J, Cheng N, et al. Prophylaxis against hepatitis B recurrence posttransplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin. Am J Transplant. 2010;10:1861-9.
24. Lee HW, Suh KS, Yi NJ, Yang SH, Cho EH, Cho JY, et al. Preoperative lamivudine therapy in HBV DNA positive recipients: is it always necessary? Hepatogastroenterology. 2007;54:1783-7.
25. Todd Stravitz R, Shiffman ML, Kimmel M, Puri P, Luketic VA, Sterling RK, et al. Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation. Liver Int. 2010;32:1138-45.
26. Luo Y, Lo CM, Cheung CK, Lau GK, Fan ST, Wong J. Identification of hepatitis B virus-specific lymphocytes in human liver grafts from HBV-immune donors. Liver Transpl. 2007;13:71-9.